Better Health for All

Insufficient evidence is available to provide a meaningful score for Insmed (INSM.US) regarding the 'Better Health for All' value. The provided articles are example placeholders and do not contain relevant quantitative data, regulatory actions, or details about the company's initiatives related to health impact, accessibility, or innovation. While the materiality analysis suggests a positive alignment due to the focus on rare diseases, a score deviation from 0 requires specific, verifiable facts from the provided evidence, which are currently absent. The clinical trial results mentioned in article

are not detailed enough to assess the net health effect. Without concrete data, a neutral score is most appropriate. , , , , , , ,

Fair Pay & Worker Respect

80% of Insmed employees would recommend working at the company to a friend.

This is supported by an overall employee rating of 4.2 out of 5 stars on Glassdoor and 97% CEO approval.

Fair Trade & Ethical Sourcing

Insmed does not audit its suppliers to evaluate compliance with company standards prohibiting slavery and human trafficking.

The company states it is not aware of any element of slavery, child labor, or human trafficking in its business or supply chains, and respects fair labor laws, including prohibitions against child labor. However, it does not yet verify its direct supply chain to evaluate and address risks of slavery and human trafficking, with less than 5% of suppliers mapped beyond tier 1. While Insmed maintains a Supplier Code of Conduct and requires suppliers to comply with all applicable laws, it does not currently require direct suppliers specifically to certify that their materials are sourced or manufactured in compliance with applicable laws on slavery and trafficking, meaning less than 5% of contracts reference binding ethical clauses.

Honest & Fair Business

Insmed has a formal whistleblower protection policy with an accessible hotline.

The company also has an anti-corruption policy that mandates compliance with the U.S. Foreign Corrupt Practices Act and includes third-party due diligence, but the evidence does not detail the frequency or effectiveness of training.

Kind to Animals

Insmed has an Animal Welfare Statement, a Board-approved Code of Business Conduct and Ethics that includes animal welfare, and follows the '3Rs' (Replace, Reduce, Refine) of animal welfare.

However, the company conducts pre-clinical studies of its drugs on animals to assess product safety. Insmed states it seeks to work only with external research service providers that are accredited by AAALAC International or meet AAALAC International standards, and conducts animal research at leading, high-quality third-party facilities. There is no evidence of formal collaborations or engagement with animal welfare stakeholders to develop industry-wide animal-free testing and sourcing standards.

No War, No Weapons

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The provided articles, including the 2024 annual report, 2023 responsibility report, code of business conduct, and other company information, do not contain any specific data, policies, or actions related to arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other metric relevant to the 'No War, No Weapons' ethical value.

Consequently, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

Insmed reported Scope 1 and 2 emissions for 2023 as 2,230 tCO₂e, but explicitly stated that Scope 3 emissions data was not provided.

The company consumed 100% of its energy from grid electricity in 2023, indicating no renewable energy use. Water use at its headquarters in 2023 was 372,000 gallons. For waste, the company recycled 46.5 tons at its headquarters and 35.6 tons at its primary R&D site in 2023, along with 2,320 lbs of electronic waste recycled and 900 lbs repurposed. No regulatory violations or enforcement actions related to GMP or equivalent standards were reported, and zero recalls were issued. The company's US headquarters has a WELL Health-Safety Rating, but no percentage of green-certified buildings is provided, and this rating is not equivalent to LEED or BREEAM certification for the purpose of this KPI.

Respect for Cultures & Communities

Insmed has 8 formal partnerships with organizations such as Google Cloud, COPD Foundation, and Ronald McDonald House Charities - Japan.

The company reported zero cultural appropriation incidents. For community concerns, Insmed has a whistleblower program with a 24/7 external independent hotline and an open-door policy. The company supported Rare Disease Day by donating 1,000 kid-friendly hospital gowns and created a multicultural cookbook with employee recipes. Insmed provided funding to organizations like Starlight Children’s Foundation and two Tokyo-based Ronald McDonald Houses. Plain language summaries are used for clinical trials. Japanese cultural training is provided for managers and the Executive Committee.

Safe & Smart Tech

Insmed reported no material cybersecurity incidents for 2023 and no incidents of unauthorized data use.

The company implements security awareness training and testing for employees. It performs vulnerability scanning, penetration testing, and periodic audits of clinical trial systems, with critical vulnerabilities patched within 21-30 days on average. Insmed's privacy policy outlines user rights to access, correct, and delete data, and mentions data retention for necessary periods. The company complies with relevant U.S. and foreign laws, including GDPR and CCPA, and reported zero enforcement actions for GMP violations.

Zero Waste & Sustainable Products

Insmed responsibly manages and tracks hazardous and chemical waste in research laboratories, adhering to all applicable laws and regulations.

This material is handled by a third-party waste management company and tracked in line with regulatory requirements. In 2024, internal audits by the Safety Committee and an independent third party resulted in no significant findings, and the company passed all regulatory environmental health and safety-related inspections with no deficiencies. The company launched an office recycling program at U.S. locations, recycling 46.5 tons of waste at headquarters and 35.6 tons at its primary R&D site in 2023. In 2024, 2,552 meals were donated from the headquarters cafeteria, avoiding 3,246 lbs of food waste. The company is developing a Supplier Code of Conduct, expected to be finalized in 2025, to encourage suppliers to improve environmental management.